Bio‑Techne (TECH) CEO Form 4: 2,303 shares disposed at $62.57
Bio‑Techne (TECH) Chief Executive Officer and Director Kim Kelderman reported an insider transaction.
Rhea-AI Filing Summary
Bio‑Techne (TECH) Chief Executive Officer and Director Kim Kelderman reported an insider transaction. On 11/03/2025, he disposed of 2,303 shares of common stock at $62.57 under transaction code F, and now directly holds 48,665 shares.
The filing also lists multiple derivative awards outstanding, including stock options and restricted stock units. Examples include stock options covering 90,441 shares at an exercise price of $53.60 expiring on 08/15/2035, and performance RSUs covering 70,708 shares subject to performance-based vesting.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise Price or Tax Liability: 2,303 shares
Exercise Price or Tax Liability
18 txns
Insider
Kelderman Kim
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise Price or Tax Liability | Common Stock | 2,303 | $62.57 | $144K |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Performance Restricted Stock Units | -- | -- | -- |
| holding | Performance Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Performance Restricted Stock Units | -- | -- | -- |
| holding | Performance Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Performance Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Performance Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Common Stock — 48,665 shares (Direct);
Stock Option (Right to Buy) — 251,204 contracts (Direct);
Stock Options (Right to Buy) — 307,975 contracts (Direct);
Performance Restricted Stock Units — 140,265 contracts (Direct);
Performance Stock Options (Right to Buy) — 49,826 contracts (Direct);
Restricted Stock Units — 52,441 contracts (Direct)
Footnotes (12)
- F1. Fully exercisable.
- F2. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- F3. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F4. Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026.
- F5. Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027.
- F6. Options to purchase 12,973 shares vest on each of 2/1/2025 and 2/1/2027, and options to purchase 12,972 shares vest on each of 2/1/2026 and 2/1/2028.
- F7. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F8. 8,543 restricted stock units vest on 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027.
- F9. Options to purchase 17,265 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 17,266 shares vest on 8/15/2028.
- F10. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F11. 11,785 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028.
- F12. Options to purchase 30,147 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
AI-generated analysis. How Rhea-AI works. Not financial advice.
